Zealand Pharma A/S
ZLDPF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.24 | -0.00 | -11.58 | -4.33 |
| FCF Yield | -0.22% | 33.19% | -1.38% | -0.40% |
| EV / EBITDA | -87.46 | 2.31 | -112.77 | -166.50 |
| Quality | ||||
| ROIC | -4.96% | 48.44% | -4.62% | -4.37% |
| Gross Margin | 13.40% | 100.00% | 95.00% | 95.49% |
| Cash Conversion Ratio | 0.17 | 1.12 | 1.49 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | 198.71% | 363.19% | -20.21% | -17.36% |
| Free Cash Flow Growth | -100.82% | 1,770.61% | -177.73% | 37.99% |
| Safety | ||||
| Net Debt / EBITDA | 2.48 | -0.84 | 1.18 | 0.32 |
| Interest Coverage | -10.34 | 1,136.02 | -53.20 | -48.29 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.04 | 0.04 | 0.04 |
| Cash Conversion Cycle | -2,910.44 | -66,284.29 | -50,253.24 | -36,247.02 |